?

        當前位置:標準品 > 標準物質 >
        用于脊髓灰質炎1型脊髓灰質炎病毒的MAPREC測定的低突變病毒參考(沙賓
        ??【編號】:NIBSC00/416

        ??【名稱】:用于脊髓灰質炎1型脊髓灰質炎病毒的MAPREC測定的低突變病毒參考(沙賓

        ??【規(guī)格】:個

        ??【價格】:2600元

          用于脊髓灰質炎1型脊髓灰質炎病毒的MAPREC測定的低突變病毒參考(沙賓)(第一國際參考制劑)

          編號:NIBSC00/416
          英文:Low Mutant Virus Reference for MAPREC assay of poliovirus type 1 (Sabin)(1st International Reference Preparation)
          標準類型:國際參考制劑
          規(guī)格:1個 
        Customer Notes 00/410 - MAPREC assay of poliovirus type 1 (Sabin).100% 480-A, 525-C DNA(1st International Reference Preparation) 00/418 - MAPREC assay of poliovirus type 1 (Sabin) (1st International Standard) 00/422 - MAPREC assay of poliovirus type 1 (Sabin)High Mutant Virus Reference(1st International Reference Preparation)
          描述:1. INTENDED USE
        This Low Mutant Virus Reference (LMVR) is intended to be used as a
        control to determine whether an individual determination is valid in the
        MAPREC assay. The % 480-A and 525-C content of the candidate
        reference materials were chosen such that the biological variation
        inherent in the MAPREC method would lead to an invalid result in only
        about 1 in 100 determinations.
        2. CAUTION
        This preparation is not for administration to humans or animals in
        the human food chain.
        The material is of bovine origin. The material is certified to be obtained
        from animals taken from a closed herd in the female line since 1980, in
        which no animal has been clinically suspected of having BSE & which
        has not been fed rations containing ruminant derived protein during
        that period.
         As with all materials of biological origin, this preparation should be
        regarded as potentially hazardous to health. It should be used and
        discarded according to your own laboratory's safety procedures. Such
        safety procedures should include the wearing of protective gloves and
        avoiding the generation of aerosols. Care should be exercised in
        opening ampoules or vials, to avoid cuts.
        3. UNITAGE
        00/416 is assigned a value of 1.84% 480-A, 525-C, on the basis of a
        WHO collaborative study.
        4. CONTENTS
        Country of origin of biological material: USA.
        Each vial contains approximately 0.5ml of poliovirus type 1 (Sabin) grown
        in serum free medium. Two poliovirus stocks containing 100% 480-A,
        525-C, and 100% 480-G, 525-T were produced by PCR site directed
        mutagenisis from cloned DNA. This DNA was reverse transcribed in vitro
        and transfected into HEp2c cells. Before preparing the bulk, the stocks
        were mixed in different proportions and tested by MAPREC to determine
        the appropriate volumes of stock in the final bulk suspension that was
        filled as 00/416.
        5. STORAGE
        The material should arrive frozen.
        Unopened ampoules should be stored at –70°C or below.
        6. DIRECTIONS FOR OPENING
        Vials have a „flip-up? circular cap. Either on the cap or the collar of the
        vial, there is an indication of the point at which to lever off the cap. This
        exposes an area of the stopper through which reconstitution and
        withdrawal of the preparation can be made using a hypodermic needle
        and syringe. If use of a pipette is preferred, then fully remove the metal
        collar using, for example, forceps, taking care to avoid cuts by wearing
        appropriate gloves. Remove the stopper for access. Care should be
        taken to prevent loss of the contents.
        7. USE OF MATERIAL
        A Standard Operating Procedure for the MAPREC assay is available
        from; Chief, Biologicals, World Health Organization. This procedure
        requires that an aliquot of 00/416 is tested in each MAPREC assay and
        used to validate the test.
        8. STABILITY
        Reference materials are held at NIBSC within assured, temperaturecontrolled
        storage facilities. Reference Materials should be stored on
        receipt as indicated on the label.
        NIBSC follows the policy of WHO with respect to its reference materials.
        9. REFERENCES
        a) WHO (2002) WHO Technical Report Series, 904, 31-91.
        b) European Pharmacopoeia, 6th Edition (2009) Vaccines for human use,
        Poliomyelitis vaccine oral 04/2008:0215.
        c) WHO/BS/09.2103. WHO Technical Report Series.
        10. ACKNOWLEDGEMENTS
         We would like ackowledge the help of the participants of the WHO
        collaborative study to evaluate the Poliovirus type 1 MAPREC assay. 
          聲明:此對照品、標準品由【中檢計量】提供網(wǎng)站查詢購買服務
          注:點擊cas,或者搜索:名稱、編號、cas均可顯示價格
        上一篇:脊髓灰質炎病毒1型(Sabin)的MAPREC分析100%480-A,525-C DNA(1st國際參考制 下一篇:沒有了



          ?
          首 頁 | 對照品| 標準品| 標準物質| 實驗試劑| 培養(yǎng)基| 菌種購買| 新聞中心| 聯(lián)系我們| 網(wǎng)站地圖

          2011-2018 中檢計量-萊耀生物@版權所有

          ? 主站蜘蛛池模板: 南木林县| 四平市| 华阴市| 中阳县| 平南县| 绥芬河市| 宜黄县| 梁平县| 璧山县| 双城市| 建瓯市| 塘沽区| 兴业县| 库伦旗| 柯坪县| 滨州市| 镇康县| 兴安盟| 高碑店市| 色达县| 柯坪县| 张掖市| 苗栗县| 呼图壁县| 仲巴县| 长宁县| 天峨县| 黄平县| 乐清市| 长宁县| 慈溪市| 固原市| 临海市| 永靖县| 锡林郭勒盟| 德惠市| 临武县| 武功县| 乌拉特前旗| 武城县| 徐汇区|